News
JNJ
148.44
-3.70%
-5.70
The Smartest Dividend Stocks to Buy With $5,000 Right Now
The Motley Fool · 6h ago
Big Pharma Counted on This Loophole. It May Be Closing.
Barron‘s · 10h ago
Trump Unveils 'Historic And Transformative' $600 Billion Saudi Deal, Predicts Markets Will 'Go a Lot Higher'
Benzinga · 11h ago
Noteworthy Tuesday Option Activity: NATL, ABNB, JNJ
NASDAQ · 12h ago
13 Analysts Have This To Say About Johnson & Johnson
Benzinga · 13h ago
Big Pharma Counted On a Price Negotiation Loophole. It May Be Closing.
Barron‘s · 13h ago
Peering Into Johnson & Johnson's Recent Short Interest
Benzinga · 14h ago
UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
TipRanks · 15h ago
XLV, JNJ, ABBV, DHR: ETF Inflow Alert
NASDAQ · 16h ago
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
Barron‘s · 16h ago
Fund Update: DIMENSIONAL FUND ADVISORS LP Just Disclosed New Holdings
NASDAQ · 16h ago
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance
TipRanks · 16h ago
Johnson & Johnson Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 17h ago
Johnson & Johnson Price Target Cut to $153.00/Share From $169.00 by Leerink Partners
Dow Jones · 17h ago
Leerink Partners Downgrades Johnson & Johnson to Market Perform, Lowers Price Target to $153
Benzinga · 17h ago
J&J, Halozyme cut at Leerink on price control risk for combo products
Seeking Alpha · 17h ago
Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls
TipRanks · 17h ago
Dow's 150-point fall led by losses for UnitedHealth, Merck stocks
MarketWatch · 18h ago
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
NASDAQ · 18h ago
JNJ Quantitative Stock Analysis
NASDAQ · 18h ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
More
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Recently
Symbol
Price
%Change
    DTM
  • 102.42
  • +2.25%